Akebia Therapeutics Stock
Akebia Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- John Butler
- Employees
- 194
- Market cap
- $186 M
- IPO
- 20/03/2014
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III…
Akebia Therapeutics stock: price history
1D
-3.7%
1W
-16.4%
1M
-27.0%
6M
-52.5%
YTD
-58.4%
1Y
-77.1%
2Y
-49.6%
5Y
-76.5%
10Y
-91.7%
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~41% stronger price swings than usual
Ask the agents about Akebia Therapeutics
Analyst assessment of Akebia Therapeutics
PRICE TARGET LOW
US$1.00
CONSENSUS
US$1.00
MEDIAN
US$1.00
PRICE TARGET HIGH
US$1.00
0
STRONG BUY
7
BUY
4
HOLD
1
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 15/09/2026
Akebia Therapeutics stock metrics
P/E
-6.2
P/B
7.22
EV/EBITDA
-4.58
RETURN ON EQUITY
-35.6%
NET MARGIN
-18.1%
DEBT/EQUITY
2.16
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.3%
FLOAT SHARES
269,582,849
AVG. DAILY VOLUME (30D)
6,875,166
Insider transactions (SEC)
Butler John P.
Ostrowski Erik
ROGERS MICHAEL W
ADAMS ADRIAN
Smith Cynthia
Institutional holders
Comparable stocks
Frequently asked questions about Akebia Therapeutics stock
What does Akebia Therapeutics do?
Akebia Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is John Butler, the company employs around 194 people.
The IPO was on 20/03/2014; the stock trades on NASDAQ under the ticker AKBA.
What do analysts say about Akebia Therapeutics stock?
12 analysts rate the stock, the consensus is Buy (as of 15/09/2026).
The average price target is US$1.00, ranging from US$1.00 to US$1.00, with a median of US$1.00.
This is an external assessment, not a statement by Market Jury.
When does Akebia Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 41% stronger than usual.
Does Akebia Therapeutics pay a dividend?
No, Akebia Therapeutics currently does not pay a dividend.
Which stocks are comparable to Akebia Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Akebia Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Akebia Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.